Skip Navigation

Details for High Impact Journal

Maintenance notice: We are currently addressing issues with broken links due to recent major website changes. We apologize for any inconvenience and appreciate your patience. Please contact brittany.trottier@niehs.nih.gov for assistance.

Superfund Research Program

Gastroenterology (impact factor: 22.682)

2023

  • Huang DQ, Wilson LA, Behling C, Kleiner D, Kowdley KV, Dasarathy S, Amangurbanova M, Terrault N, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Loomba R, Allende D, Bellar A, Dasarathy J, Guy C, Kopping M, Piercy D, Suzuki A, Tawadrou N, Cruz M, Cummings OW, Garrison L, Gawrieh S, Samala N, Vuppalanchi R, Carpenter D, Cattoor T, Freebersyser J, Angkanaworakul P, Berihun A, Buysse A, Dorrian T, Gulati B, Liu K, Misic S, Sohal A, Vuong J, Ajmera VH, Madamba E, Middleton MS, Richards L, Singh S, Sirlin C, Gill R, Hameed B, Awe R, Olvera D, Yuan L, Yeh M, Albhaisi S, Asgharpour A, Boyett S, Contos MJ, Luketic VA, Schlosser J, Siddiqui MS, Adamo P, Belt P, Clark JM, DeSanto JM, Meinert J, Miriel L, Mitchell EP, Shade C, Smith J, Smith M, Sternberg A, Natta ML, Wagoner A, Woreta T, Yates KP. 2023. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 165(2):463-472. doi:10.1053/j.gastro.2023.04.025 PMID:37127100

2021

  • Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong VW, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. 2021. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657-1669. doi:10.1053/j.gastro.2021.07.049 PMID:34602251 PMCID:PMC8819923
  • Loomba R, Ratziu V, Harrison SA. 2021. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162(3):doi:10.1053/j.gastro.2021.10.051 PMID:34822801

2020

  • Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Wisplinghoff H, Gao B, Kasper P, Roderburg C, Tacke F, Steffen H, Goeser T, Abraldes JG, Tu XM, Loomba R, Starkel P, Pride D, Fouts DE, Schnabl B. 2020. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology 159:1839-1852. doi:10.1053/j.gastro.2020.07.005 PMID:32652145
  • Loomba R, Lim JK, Patton H, El-Serag HB. 2020. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 158:1822-1830. doi:10.1053/j.gastro.2019.12.053 PMID:32006545 PMCID:PMC8012107

2019

2018

  • Ajmera VH, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, Hooker J, Sy E, Behling C, Xu R, Middleton MS, Valasek MA, Faulkner C, Rizo E, Richards L, Sirlin CB, Loomba R. 2018. Magnetic Resonance Imaging Proton Density Fat Fraction Associates with Progression of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 155(2):307-310. doi:10.1053/j.gastro.2018.04.014 PMID:29660324 PMCID:PMC6090543

2017

  • Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Valasek MA, Rizo E, Brenner DA, Sirlin CB, Loomba R. 2017. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152(3):598-607.e2. doi:10.1053/j.gastro.2016.10.026 PMID:27911262 PMCID:PMC5285304

2016

2015

2014

2013

  • Yang L, Inokuchi-Shimizu S, Roh Y, Song J, Loomba R, Park E, Seki E. 2013. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology 144(5):1042-1054. doi:10.1053/j.gastro.2013.01.056 PMID:23391818 PMCID:PMC3752402

2012

1998

  • Campbell-Thompson M, Reyher KK, Lauwers GY, Shiverick KT. 1998. Estrogens modulate gastro-duodenal hyerplasia and dysplasia induced by N-methyl-N'-nitrosoguanidine in rats. Gastroenterology 114(4):G2347.
Back
to Top